following a full submission assessed under the end of life and orphan equivalent medicine process:
serplulimab (Hetronifly®) is not recommended for use within NHSScotland.
Indication under review: in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
In a randomised, double-blind, phase III study in patients with previously untreated ES-SCLC serplulimab plus carboplatin and etoposide significantly improved overall survival compared with placebo plus carboplatin and etoposide.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- serplulimab (Hetronifly)
- SMC ID:
- SMC2840
- Indication:
In combination with carboplatin and etoposide for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC).
- Pharmaceutical company
- Accord Healthcare
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 19 January 2026